Professur für Translationale Frauenheilkunde und Geburtshilfe

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019 (2019) Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, Blohmer J, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 (2019) Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, et al. Journal article Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer (2019) Ruddy KJ, Schaid DJ, Partridge AH, Larson NB, Batzler A, Häberle L, Dittrich R, et al. Journal article Mutational diversity and therapy response in breast cancer: A sequencing analysis in the neoadjuvant geparsepto trial (2019) Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al. Journal article Fatal events during clinical trials: an evaluation of deaths during breast cancer studies (2019) Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching P, et al. Journal article Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus (2019) Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, et al. Journal article Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice (2019) Schneeweiss A, Denkert C, Fasching P, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ Journal article Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer (2019) Fasching P, Gaß P, Häberle L, Volz B, Hein A, Hack C, Lux MP, et al. Journal article Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620 (2019) Untch M, Loibl S, Fasching P Journal article, Letter Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019) Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al. Journal article